SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001760460-23-000010
Filing Date
2023-10-18
Accepted
2023-10-17 21:05:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 13DA-4.htm SC 13D/A 49038
  Complete submission text file 0001760460-23-000010.txt   50654
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Subject) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88741 | Film No.: 231330789
SIC: 2834 Pharmaceutical Preparations

Mailing Address 950 THIRD AVENUE FL 25 NEW YORK NY 10022
Business Address 950 THIRD AVENUE FL 25 NEW YORK NY 10022 2128783702
Puissance Life Science Opportunities Fund VI (Filed by) CIK: 0001760460 (see all company filings)

IRS No.: 320567422 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A